Navigation Links
Long-term Follow Up Interim Data Show Nplate(TM) Increased and Sustained Platelet Counts in Adult Chronic ITP Patients
Date:12/8/2008

SAN FRANCISCO, Dec. 8 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today released updated results from the ongoing, open-label extension study of the long-term safety and efficacy of Nplate(TM) (romiplostim) in adult patients with chronic immune thrombocytopenic purpura (ITP). Chronic ITP is a chronic and serious autoimmune disorder characterized by lower than expected platelet counts in the blood, sometimes leading to serious bleeding events. The results were presented today as an oral presentation at the 50th Annual Meeting of the American Society of Hematology (ASH Abstract # 402). Results from a study of Nplate in myelodysplastic syndromes (MDS) also were presented.

"These data show Nplate increased platelet counts in most patients for most of the time, and clinically relevant bleeding was reduced over time," said David J. Kuter, M.D., Chief of Hematology, Massachusetts General Hospital, Boston. "This is significant because Nplate can be a long-term treatment for adult chronic ITP patients, who are at risk of serious bleeding events if their platelet counts drop to less than 30,000 per microliter. These patients have had limited availability to long term treatment options."

These study results showed that overall 74 percent of patients (160/215) achieved a platelet response defined as a platelet count of 50,000 platelets per microliter and doubling of the baseline platelet count (median:17,000 platelets per microliter). A platelet response was achieved by 30 percent (61/207) of patients after the first dose and by 47 percent (94/199) of patients after the third dose. The average treatment period was 76 weeks and the longest duration of treatment was 204 weeks.

Additional key findings from the Extension study show:

-- Platelet counts increased: Platelet counts of Nplate-treated pati
'/>"/>

SOURCE Amgen Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP
2. Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
3. Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients
4. Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults
5. CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohns Disease Patients
6. Continuous Treatment With Abbotts HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment
7. Long-Term Phase I and Phase I/II Trial Data Continue to Show Striking Improvement in Survival of Brain Cancer Patients Who Receive DCVax(R)-Brain
8. Medivation Presents Positive New Data on Dimebons Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimers Disease
9. Precise Low-Dose Drug Monitoring Essential for Long-Term Kidney Transplant Success
10. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
11. Patients Own Infection-Fighting T Cells Put Late-Stage Melanoma Into Long-Term Remission - Without Chemotherapy or Radiation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... In accordance with Rule 17.1 and Rule 2.9 ... United States Exchange Act, Echo Pharma Acquisition Limited ("Royalty Pharma") ... (NYSE: ELN). Background On 2 May ... for the entire of the issued and to be issued ... On 20 May 2013, Royalty Pharma announced ...
(Date:5/24/2013)... The potential of the pulmonary route as ... has been receiving undeniable attention with the recent advances ... crucial formulation considerations for orally inhaled products together with ... in the efficiency of pulmonary delivery, and great strides ... techniques and devices in recent years. With ...
(Date:5/23/2013)... , May 24, 2013 3SBio ... the "Company"), a leading China ... and marketing biopharmaceutical products, announced today that, at ... the Company,s shareholders voted in favor of the ... agreement and plan of merger dated February 8, ...
Breaking Medicine Technology:Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 9Inhalaltion Drug Delivery: 11-12 September - Berlin, Germany 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 3
... a clinico-molecular informatics company, today announced the commercialization ... lines that translate patient-specific molecular and genomic data, ... more effective drug choices for patients. ... drastically and clinical data becoming increasingly accessible, today,s ...
... /PR Newswire-Asia/ -- Global Pharm Holdings Group, Inc. ... growing vertically integrated pharmaceutical company engaged in the ... processing, and herbal cultivation and sales in China ... Shandong provinces, today announced the appointment of Mr. ...
Cached Medicine Technology:MolecularHealth to Introduce Knowledge-Driven Solutions that Enhance Drug Safety and Enable Molecularly-Guided Treatment Decision Support 2MolecularHealth to Introduce Knowledge-Driven Solutions that Enhance Drug Safety and Enable Molecularly-Guided Treatment Decision Support 3Global Pharm Holdings Group, Inc. Strengthens its Board by Adding a Non-Executive Director 2Global Pharm Holdings Group, Inc. Strengthens its Board by Adding a Non-Executive Director 3
(Date:5/25/2013)... 25, 2013 Pradaxa lawsuits ... episodes of internal bleeding while using the blood thinner continue ... Court, Southern District of Illinois, Bernstein Liebhard LLP reports. ... side effect claims had been filed in the ... 705 claims reported by the Court on May 15th. ( ...
(Date:5/25/2013)... (PRWEB) May 25, 2013 On May ... brain cancer research and advocacy, comments on a new ... that shows incorporating cold atmospheric plasma into brain cancer ... , According to a Science Daily article, ... (MPE), biologists and physicians demonstrated the “synergistic effect of ...
(Date:5/25/2013)... Dr. Farooq Ashraf, founder of the Atlanta Vision ... his practice’s adoption of The iFS Advanced Femtosecond Laser. ... proven with more than 10 years of clinical research ... “We are happy to announce that we will now ... LASIK practice,” Ashraf said Thursday. “We have been using ...
(Date:5/25/2013)... The Slim Weight Patch has been clinically proven many ... to the highly sought after ingredients that have been used ... extra 2 months supply & premium membership of Slimming+ to ... you desire faster than ever. , Click Here to ... weight patch consumers can observe instant results within only a ...
(Date:5/25/2013)... For college students, few events ... they are turning to prescription stimulants like Adderall ... more on this, go to http://www.sciencedaily.com/releases/2013/05/130501145151.htm . ... that students who pick up Adderall, “just to ... developing a physical and psychological dependency. While initially ...
Breaking Medicine News(10 mins):Health News:Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports 2Health News:Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports 3Health News:Voices Against Brain Cancer Comments on Study that Shows Cold Plasma’s Success Against Brain Cancer Cells 2Health News:Atlanta Vision Clinic Acquires the Latest in Blade-Free Lasik Technology Bringing Dubai Patients the Intralase Method 2Health News:Slim Weight Patch Advanced Weight Loss System Offers Extra Two Month Supply and Membership for Maximum Weight Loss 2Health News:Addiction and Drug Abuse: Study Drug Adderall Abuse Spikes During Finals 2
... 12 Quest Diagnostics Incorporated (NYSE: DGX ... and services, announced today that it will report fourth-quarter ... for 2009 on Monday, January 26, before the market ... investors to discuss the results beginning at 8:30 a.m. ...
... Lilly and Company,(NYSE: LLY ) today filed ... (SEC) detailing the pro forma impact of the company,s ... available on the,SEC,s website at www.sec.gov and ... www.investor.lilly.com . , The content ...
... VANCOUVER, Jan. 12 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI ... million for the quarter and $141.9 million for the full ... quarter declined by 32.7% over the same quarter in 2007 ... annual sales in 2007. Sales in the U.S. for the ...
... Ranir, LLC, a leading,consumer products oral care company, ... foremost manufacturer and marketer of interdental oral,care products ... San Diego,California, Placontrol is the founder of the ... disclosed. , Ranir, headquartered ...
... Genomma Lab Internacional,S.A.B. de C.V. (BMV: LAB) ("Genomma ... the Company signed an agreement with IXE Casa de ... for the Company,s outstanding shares, thus,becoming another company to ... valid upon approval of the Mexican Stock Exchange (Bolsa,Mexicana ...
... has negative impact- No similar material exposures are expected ... wins are strong; service revenue expected to increase by ... Corporation (Nasdaq: PRXL ) has received notification ... unable to continue to make payments that are due ...
Cached Medicine News:Health News:Quest Diagnostics to Release Fourth Quarter and Full Year 2008 Financial Results 2Health News:QLT announces Visudyne(R) sales for fourth quarter and fiscal year 2008 2Health News:Ranir, LLC Announces the Acquisition of Placontrol, Inc. 2Health News:Genomma Lab, New Participant in Market-Maker Program 2Health News:PAREXEL Reports Preliminary Second Quarter Results 2Health News:PAREXEL Reports Preliminary Second Quarter Results 3Health News:PAREXEL Reports Preliminary Second Quarter Results 4Health News:PAREXEL Reports Preliminary Second Quarter Results 5Health News:PAREXEL Reports Preliminary Second Quarter Results 6
The OneTouch Flexx Professional Blood Glucose Monitoring System with OneTouchPro Test Strips sets the standard for safety and convenience with unique off-meter sample application and a wide range of ...
... the market in New Technology, the Arrow ... whole new first and only IABP system ... a physiologically based timing algorithm, WAVE, to ... accuracy. Second generation Automaticity provides for ...
... NEXES Special Stains automated system ... to provide enhanced consistency of ... stains. Proprietary kinetic technology, including ... Mixing, assures high quality routine ...
... NexES IHC, the worlds first ... staining system introduced a whole ... while combining system modularity and ... laboratory productivity. The NexES Systems ...
Medicine Products: